TransEnterix (NYSEAMERICAN:TRXC) Trading Down 5%

Shares of TransEnterix, Inc. (NYSEAMERICAN:TRXC) fell 5% during mid-day trading on Tuesday . The company traded as low as $0.19 and last traded at $0.19, 3,984,003 shares were traded during trading. An increase of 43% from the average session volume of 2,787,802 shares. The stock had previously closed at $0.20.

TRXC has been the subject of several research analyst reports. Royal Bank of Canada lowered TransEnterix from an “outperform” rating to a “sector perform” rating and set a $1.00 price target for the company. in a research note on Thursday, August 8th. Zacks Investment Research upgraded TransEnterix from a “hold” rating to a “buy” rating and set a $0.25 price objective on the stock in a report on Saturday, November 16th.

TransEnterix (NYSEAMERICAN:TRXC) last released its quarterly earnings data on Tuesday, November 12th. The medical instruments supplier reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). The business had revenue of $2.02 million for the quarter, compared to the consensus estimate of $4.68 million.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC lifted its stake in shares of TransEnterix by 921.4% during the second quarter. SG Americas Securities LLC now owns 212,259 shares of the medical instruments supplier’s stock worth $289,000 after purchasing an additional 191,477 shares in the last quarter. First Trust Advisors LP raised its holdings in shares of TransEnterix by 62.4% during the 2nd quarter. First Trust Advisors LP now owns 706,949 shares of the medical instruments supplier’s stock valued at $961,000 after buying an additional 271,502 shares during the period. Swiss National Bank raised its holdings in shares of TransEnterix by 8.9% during the 2nd quarter. Swiss National Bank now owns 343,300 shares of the medical instruments supplier’s stock valued at $467,000 after buying an additional 28,200 shares during the period. Alps Advisors Inc. lifted its position in TransEnterix by 129.6% during the 2nd quarter. Alps Advisors Inc. now owns 491,900 shares of the medical instruments supplier’s stock worth $669,000 after acquiring an additional 277,678 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in TransEnterix by 165.9% during the 2nd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 174,687 shares of the medical instruments supplier’s stock worth $238,000 after acquiring an additional 108,981 shares in the last quarter.

TransEnterix Company Profile (NYSEAMERICAN:TRXC)

TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.

Recommended Story: How a Strangle Strategy is different from a Straddle Strategy

Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.